RLT

Bestqool proves the effectiveness and safety of its red light therapy device with a professional third-party Report

Retrieved on: 
星期三, 四月 17, 2024
Physical, Enzyme, Cell, RLT, Safety, Skin, Tissue, Bacteria, NASA, Weight loss, System, Carbon, Plant, Mitochondrion, Oxygen, Phagocytosis, Vasodilation, Medicine, Virus, Nutrient, Regeneration, Food preservation

Bestqool , a leading manufacturer in the industry of red light therapy, offers lifestyle game-changing devices that prioritize safety, efficacy, and user comfort.

Key Points: 
  • Bestqool , a leading manufacturer in the industry of red light therapy, offers lifestyle game-changing devices that prioritize safety, efficacy, and user comfort.
  • The utilization of red light therapy in well-being has its roots dating back to ancient Greek times.
  • Unlike ultraviolet light, red light is harmless to the skin and does not tan or cause dark spots to the skin.
  • One of the crucial factors that the reader needs to pay attention to when buying red light therapy is RLT device irradiance.

Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer

Retrieved on: 
星期四, 五月 2, 2024
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Cancer, RLT, Atlas, Atlas Venture, Doctor of Philosophy, Centerview Partners, Research, Carcinoma, Biomedicine, Science, Biomedical Research, Acquisition, Radiopharmaceutical, Drug discovery, Medical imaging

The acquisition brings together Mariana Oncology’s innovative radiopharmaceutical pipeline and platform with the proven clinical development and commercialization expertise of Novartis.

Key Points: 
  • The acquisition brings together Mariana Oncology’s innovative radiopharmaceutical pipeline and platform with the proven clinical development and commercialization expertise of Novartis.
  • “Novartis is an established leader in the commercialization of radiopharmaceuticals with a world-class team and global reach.
  • Together, we offer a compelling combination of capabilities,” said Simon Read, Founder and CEO, Mariana Oncology.
  • Centerview Partners LLC served as financial advisor, and Goodwin Procter as legal counsel to Mariana Oncology on the transaction.

PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis

Retrieved on: 
星期二, 四月 30, 2024
Health, Research, Radiology, Pharmaceutical, Science, Biotechnology, RLT, Oncology, NVS, JPY, Partnership, PDC, Patient, Peptide, Pharmaceutical industry

PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) today announced an expansion of its peptide discovery collaboration with Swiss-based Novartis Pharma AG (“hereinafter Novartis”) (NYSE: NVS).

Key Points: 
  • PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) today announced an expansion of its peptide discovery collaboration with Swiss-based Novartis Pharma AG (“hereinafter Novartis”) (NYSE: NVS).
  • Under the multi-program agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (“PDPS®”) technology to identify and optimize novel macrocyclic peptides against targets selected by Novartis, for potential conjugation to radionuclides (to which Novartis refers to as “radioligand therapies” or “RLTs”) or other applications for both therapeutic and diagnostic purposes.
  • Under the terms of the agreement, PeptiDream will receive an upfront payment of $180 million USD (28.03 billion JPY*1) from Novartis.
  • “We are delighted to further expand our long-standing macrocyclic peptide discovery collaboration with Novartis, adding additional peptide RLT and other programs to our strong partnership,” said Patrick C. Reid, Ph.D., CEO of PeptiDream.

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors

Retrieved on: 
星期二, 四月 23, 2024
FDA, Lutetium (177Lu) oxodotreotide, Brain, Cancer, Prostate, RLT, Hospital, Food, CHOP, Breast, B cell, Somatostatin, Disease, Incidence, Patient, Lung, National Cancer Institute, Diagnosis, Children's Hospital of Philadelphia, NETS, Ageing, Pharmaceutical industry

This approval makes Lutathera the first therapy specifically reviewed and approved for use in pediatric patients with GEP-NETs.

Key Points: 
  • This approval makes Lutathera the first therapy specifically reviewed and approved for use in pediatric patients with GEP-NETs.
  • "Lutathera is now the very first therapy approved specifically for children with GEP-NETs, offering new hope to young patients living with this rare cancer," said Tina Deignan, Therapeutic Area Head, Oncology US.
  • NETs are a type of cancer that originates in neuroendocrine cells throughout the body and are commonly considered slow-growing malignancies1.
  • In addition, the estimated radiation absorbed dose in pediatric patients was within established organ thresholds for external beam radiation and comparable to that in adults for the approved dose.

Bestqool Launches Innovative Red Light Therapy Devices for Eczema Relief

Retrieved on: 
星期五, 四月 5, 2024
Skin care, Fibroblast, Health, Certification, RLT, Psoriasis, Adenosine triphosphate, Cell, Serotonin, Patient, Photobiology, Tissue, Rosacea, Mitochondrion, Mental health, History, Red, Quality of life, Dermatitis, Itch, Keratinocyte, Acne, Skin, Pollution, Erythema, Cytokine, Irritation, ATP, Immune system, Recurrence, Fatigue, Swelling, FDA, Waste, Medical device

Bestqool's advanced red light therapy offers a non-invasive, natural solution for managing this pervasive skin issue.

Key Points: 
  • Bestqool's advanced red light therapy offers a non-invasive, natural solution for managing this pervasive skin issue.
  • Combining red light therapy with topical ointments can be a complementary approach for effective eczema treatment.
  • Bestqool's latest range of portable red light therapy devices are designed to be both convenient and effective for home use.
  • Adding red light therapy to daily care and prevention can repair both inside and outside by lowering eczema recurrence and improving the quality of life.

Bestqool Revolutionizes Outdoor Activities with Innovative Red Light Therapy Devices

Retrieved on: 
星期三, 四月 3, 2024
RLT, Psoriasis, Motivation, Exercise, Chemical oxygen demand, System, Mitochondrion, Motion, Joint, Life, Athlete, Acne, Facial muscles, Skin, Oxygen, Red light, Health, Low-level laser therapy, Medical imaging

Seattle, Washington, April 03, 2024 (GLOBE NEWSWIRE) -- Bestqool has announced its innovative approach to integrating Red Light Therapy (RLT) with outdoor exercises and sports routines.

Key Points: 
  • Seattle, Washington, April 03, 2024 (GLOBE NEWSWIRE) -- Bestqool has announced its innovative approach to integrating Red Light Therapy (RLT) with outdoor exercises and sports routines.
  • Red Light Therapy is an advanced therapy mode that uses low-level wavelengths of red light to focus on the skin or deeper tissues, as needed to help resolve their related issues.
  • [2]
    Because of the invention of several hand-held devices, using Red Light Therapy within the comforts of your home has also been made possible.
  • When it comes to talking about top-notch, great-quality hand-held Red Light Therapy devices, Bestqool is your ultimate solution.

Bestqool Unveils Comprehensive Guide to Optimize Red Light Therapy Dosage for Enhanced Health Benefits

Retrieved on: 
星期一, 三月 18, 2024
Research, Health, RLT, Brain, Tendon, Light-emitting diode, Light, Photon, Overalls, Joint, Skin, Safety, FDA, Medical imaging

Seattle, Washington, March 18, 2024 (GLOBE NEWSWIRE) -- In a groundbreaking effort to enhance the effectiveness of red light therapy, Bestqool , a leading provider of FDA class-II cleared red light therapy devices, has released an extensive dosing guide for users.

Key Points: 
  • Seattle, Washington, March 18, 2024 (GLOBE NEWSWIRE) -- In a groundbreaking effort to enhance the effectiveness of red light therapy, Bestqool , a leading provider of FDA class-II cleared red light therapy devices, has released an extensive dosing guide for users.
  • Red light therapy is applied to the body within the specific ranges of the wavelength 660 – 850 nm.
  • Bestqool's comprehensive dosing guide provides actionable advice for users, including:
    Getting the proper dosage of red light therapy is absolutely important.
  • ● Skin requires between 60-90 joules of red light therapy (660 nm) every session, which Users can obtain by doing the following:
    ● Users should place yourself between 3 and 12 inches away from the light if you're using red light for anti-aging or general skin health.

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
星期五, 四月 5, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, RLT, FAP, Doctor of Philosophy, AACR, Investigational New Drug, Event, Poster, Pharmaceutical industry

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for IM-3050, the company’s lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activation protein (FAP).

Key Points: 
  • Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for IM-3050, the company’s lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activation protein (FAP).
  • Jack Higgins, PhD, Chief Scientific Officer at Immunome, will present the data in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2024, which is taking place April 5-10 in San Diego, California.
  • “FAP is an attractive target for cancer therapy, but trials with first-generation FAP-RLTs have produced modest clinical responses, indicating the need for novel agents with improved therapeutic properties,” commented Dr. Higgins.
  • A copy of the poster will be available on the Events & Presentations section of Immunome’s website following the conference.

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Retrieved on: 
星期四, 三月 28, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Research, RLT, FAP, Ayala, NDA, Acquisition, Executive Committee, Spacecraft, PIPE, Phase 3, Pharmacology, ADC, Pharmaceutical industry

We expect to add novel antibody-drug conjugates (ADCs) and radioligand therapies (RLTs) to the pipeline through internal discovery efforts while continuing to evaluate opportunities to acquire high-quality assets on favorable financial terms.

Key Points: 
  • We expect to add novel antibody-drug conjugates (ADCs) and radioligand therapies (RLTs) to the pipeline through internal discovery efforts while continuing to evaluate opportunities to acquire high-quality assets on favorable financial terms.
  • Immunome expects to report topline data for the ongoing Phase 3 RINGSIDE Part B trial of AL102 in the first quarter of 2025.
  • In parallel, Immunome is evaluating and performing additional manufacturing and pharmacology work required to support an NDA submission of AL102.
  • Immunome reported a net loss of $106.8 million, or basic and diluted net loss per share attributable to common stockholders of $5.38, for the year ended December 31, 2023.

Ariceum Therapeutics to present new radioligand therapy data at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
星期四, 四月 4, 2024
Diagnosis, Research, RLT, Radionuclide, UCB, Tissue, Messenger, Abstract (summary), AACR, Therapy, Macrocycle, Poster, Annual general meeting, Peptide, Pharmaceutical industry

The findings describe the selection and initial characterization of macrocyclic peptides against an undisclosed target discovered using UCB's mRNA-display technology platform, ExtremeDiversity™.

Key Points: 
  • The findings describe the selection and initial characterization of macrocyclic peptides against an undisclosed target discovered using UCB's mRNA-display technology platform, ExtremeDiversity™.
  • Macrocyclic peptides are potent ligands for radioligand therapeutics (RLT) that aim to selectively deliver radioisotopes to cancer tissues to eradicate tumor cells while limiting the damage to surrounding tissues.
  • These data have positive implications for the future development of RLT and are a potential game-changer in precision cancer therapy.
  • AACR's Annual Meeting is the perfect industry forum at the forefront of cancer research at which to present our findings."